Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
Authors
William Ho
FLX Bio, South San Francisco, CA
William Ho, Nicole Nasrah, Dan Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT03674567
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr TPS24)
DOI
10.1200/JCO.2019.37.8_suppl.TPS24
Abstract #
TPS24
Poster Bd #
J2
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
First Author: John D. Powderly II
Poster
2023 ASCO Annual Meeting
Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.
First Author: Dirk G. Brockstedt
Poster
2024 ASCO Annual Meeting
A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.
First Author: Mohamad Adham Salkeni
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe